The migration of total joint arthroplasty — historically performed exclusively in hospital inpatient settings — to ambulatory surgery centers is the most consequential channel shift in orthopedics. CMS removal of total knee and hip arthroplasty from the Inpatient Only list, combined with advances in anesthesia, pain management, and enhanced recovery protocols, has enabled same-day discharge for a growing proportion of primary joint replacement patients.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• ASC Market Size and Growth
• Procedure Migration Economics
• CMS Reimbursement Policy
• OEM ASC Commercial Strategy
• Implant and Instrument Design for ASC
• Hospital vs. ASC Competitive Dynamics
Table of Contents
1. Executive Summary
2. Market Overview
3. ASC Market Size and Growth
4. Procedure Migration Economics
5. CMS Reimbursement Policy
6. OEM ASC Commercial Strategy
7. Implant and Instrument Design for ASC
8. Hospital vs. ASC Competitive Dynamics
9. Competitive Landscape
10. Regional Market Analysis
11. Strategic Conclusions and Recommendations
12. Appendix
List of Tables
Table 1. Market Overview and Key Data 2025
Table 2. Competitive Landscape 2025
Table 3-8. Topic-Specific Analysis Tables
Table 3. Leading Suppliers — Portfolio and Strategy Assessment 2025
Table 4. M&A and Partnership Activity 2023-2025
Table 5. Regional Analysis
Table 6. Key Risks and Mitigation Strategies
Companies Profiled
Aesculap
Arthrex
DePuy Synthes
Enovis
Globus Medical
NuVasive
Smith & Nephew
Stryker
Wright Medical
Zimmer Biomet
